Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB106385 · 1 trial · 11 indications
Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after last dose of study drug.
| Arm | Type | Description |
|---|---|---|
| Treatment Group A (TGA) - INCB106385 | EXPERIMENTAL | In part 1 dose escalation, the dose levels will be escalated following a BOIN design. In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE. |
| Treatment Group B (TGB) - INCB106385+INCMGA00012 | EXPERIMENTAL | In part 1 dose escalation, the dose levels will be escalated following a BOIN design. In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE. |
| Name | Type | Description |
|---|---|---|
| INCB106385 | DRUG | INCB106385 will be administered orally QD |
| INCMGA00012 | DRUG | INCMGA0012 will be administered IV once every 4 weeks (Q4W) |
Inclusion Criteria: * Ability to comprehend and willingness to sign an ICF. * Willing and able to conform to and comply with all Protocol requirements. * Histologically or cytologically confirmed advanced/metastatic SCCHN, NSCLC, ovarian cancer, TNBC, CRPC, bladder cancer, and specified GI malignan...
Top 20 of 59 competitors
INCB106385 is an investigational small molecule being studied for the treatment of advanced solid tumors, including ovarian cancer. It is being evaluated alone or in combination with immunotherapy in a Phase 1 clinical trial.
The specific molecular target of INCB106385 has not been disclosed. It is a small molecule being studied in combination with immunotherapy for advanced solid tumors, including ovarian cancer.
INCB106385 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY.
INCB106385 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed.
INCB106385 has been studied in a Phase 1 clinical trial, NCT04580485, which evaluated the drug alone or in combination with immunotherapy in advanced solid tumors. The trial enrolled 54 participants and has been completed.
No alternative names for INCB106385 have been disclosed. It is identified solely by its investigational code name.